Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

from operations

(8,520)(13,007)(33,238)(36,685)Gain on change in fair value of contingent consideration liability

8,5096737,338673Interest and other income/ (expense), net

1942892Interest expense

(599)(95)(1,024)(378)Net loss

(591)(12,425)(26,896)(36,298)Consideration paid in excess of  noncontrolling interest

-(61,566)-(61,566)Net loss attributed to noncontrolling interest in Symphony Allegro, Inc.

-1,568-13,987Net loss attributable to Alexza common stockholders

$  (591)$(72,423)$ (26,896)$ (83,877)Net loss per share attributable to Alexza common stockholders

$
(0.01)$
(1.95)$
(0.50)$
(2.44)Shares used to compute basic and diluted net loss per share attributable to Alexza common stockholders

56,63937,06053,98734,388ALEXZA PHARMACEUTICALS, INC.(a development stage company)

CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)

(unaudited)September 30, December 31,20102009AssetsCash, cash equivalents and marketable securities

$
52,651$
9,916Other current assets1,3612,210Total current assets  

54,01222,126Property and equipment, net

24,92123,598Other non-current assets

4,516450Total assets

$
83,449$
46,174Liabilities and stockholders' deficitCurrent liabilities

$
56,918$
25,956Non-current liabilities

40,19027,344Stockholders' deficit

(13,659)(7,126)Total liabilities and stockholders' deficit

$
83,449$
46,174
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/hxhwtv/asia_pacific ... Pacific Fluoroscopy Market - Growth, Trends And Forecasts (2014 ... The Asia Pacific market ... CAGR from 2014 to 2020 Fluoroscopy is ... moving images of the interior of the body. The ...
(Date:5/27/2015)... a senior marketing associate with the animal health division of Eli Lilly ... healthcare setting in Bangkok, Thailand , will be among ... with respect and dignity is the guiding star for me and my ... a LillyPad blog . Donatelli and Lilly colleagues from ... Colombia , France , Ukraine ...
(Date:5/27/2015)... , May 25, 2015 Research ... of the "2015 Strategies in the Global ... This comprehensive seven-country report contains 650 ... current suppliers and potential market entrants identify and ... testing market during the next five years. ...
Breaking Medicine Technology:Asia Pacific Fluoroscopy Market Trends and Forecasts 2014 - 2019 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3Global Coagulation Testing Market Strategies 2015 2Global Coagulation Testing Market Strategies 2015 3
... Sept. 20 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... of,cethromycin, the Company,s lead compound, at the 47th ... September,17 - 20. A total of seven poster ... Eurofins Medinet and Micromyx, discussed in vitro,activity of ...
... -- When compared to insulin glargine, exenatide offered ... beta-cell function when used with metformin --, ... AMLN ) and Eli Lilly and Company ... treatment of exenatide injection,with insulin glargine on beta-cell ...
Cached Medicine Technology:Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7
(Date:5/27/2015)... 2015 Dr. Omar Ibrahimi, Dermatologist and ... CT has been selected as part of a controlled ... (and the only physician in Connecticut) to offer the ... the removal of submental fat (double chin). The procedure ... no surgery and minimal risks. Dr. Ibrahimi is an ...
(Date:5/27/2015)... Clearwater, Florida (PRWEB) May 27, 2015 ... accurate, impartial customer satisfaction surveys in the multiple ... user poll to determine the highest ranked Electronic ... As part of a special research focus on ... and announced those software vendors with the highest ...
(Date:5/27/2015)... Rock, AR (PRWEB) May 27, 2015 ... Medix today announce a partnership to provide CMSA's ... Medix community. This collaboration seeks to strengthen the ... measurement through CMSA’s CKP program. The mutually beneficial ... on identifying individual skills of talent in the ...
(Date:5/27/2015)... 27, 2015 Difass USA, a modern ... U.S. with its first three flagship products, Dormiva™, Relaxiva™ ... nationwide through http://www.difassusa.com . , A restful ... productivity, but some people struggle with getting the full ... a sleep aid designed to help you fall asleep ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2
... the University of Minnesota have found that cerebral malaria is related ... research is published in the current issue of the journal ... Malaria is a leading cause of death ... than 750,000 children a year, is one of the deadliest forms ...
... Mich., July 29 Stryker Corporation,(NYSE: SYK ) ... conference:, August 6, 2008 - 11:15 a.m. ... Conference New York, New York, A simultaneous ... website at http://www.stryker.com via the For Investors ...
... show that regular,monitoring of medications by physicians is ... health. Thanks to recent advances in the SMART,Registry, ... about their,patients that they never received before., ... how regularly,their chronically ill patients fill their prescriptions., ...
... developed a novel approach to treating advanced prostate cancer ... , Professor Wayne Tilley and Dr Lisa Butler of ... discovered that by using existing prostate cancer drugs in ... expect to generate better results for patients than current ...
... up in motor neurons , , TUESDAY, July 29 (HealthDay ... amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig,s ... University and Harvard Medical School. , ALS is a ... neurons in the brain and spinal cord that control ...
... the Clinical Gold Standard Drug Through 2016, According ... to a New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical and,healthcare ... has a lower discontinuation rate than that of Abbott,s,Niaspan ER ...
Cached Medicine News:Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:Stryker To Present at Investor Conference 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 3Health News:New treatment for advanced prostate cancer 2Health News:Scientists ID 'Jekyll-Hyde' Protein in Lou Gehrig's Disease 2Health News:A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: